These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

227 related items for PubMed ID: 25964170

  • 1. Moderate PEGylation of the carrier protein improves the polysaccharide-specific immunogenicity of meningococcal group A polysaccharide conjugate vaccine.
    Zhang T, Yu W, Wang Y, Hu T.
    Vaccine; 2015 Jun 22; 33(28):3208-14. PubMed ID: 25964170
    [Abstract] [Full Text] [Related]

  • 2. PEG as a spacer arm markedly increases the immunogenicity of meningococcal group Y polysaccharide conjugate vaccine.
    Huang Q, Li D, Kang A, An W, Fan B, Ma X, Ma G, Su Z, Hu T.
    J Control Release; 2013 Nov 28; 172(1):382-389. PubMed ID: 23511718
    [Abstract] [Full Text] [Related]

  • 3. Conjugation of β-glucan markedly increase the immunogencity of meningococcal group Y polysaccharide conjugate vaccine.
    Qiao W, Ji S, Zhao Y, Hu T.
    Vaccine; 2015 Apr 21; 33(17):2066-72. PubMed ID: 25728319
    [Abstract] [Full Text] [Related]

  • 4. New meningococcal C polysaccharide-tetanus toxoid conjugate Physico-chemical and immunological characterization.
    Cuello M, Cabrera O, Martinez I, Del Campo JM, Camaraza MA, Sotolongo F, Pérez O, Sierra G.
    Vaccine; 2007 Feb 26; 25(10):1798-805. PubMed ID: 17240485
    [Abstract] [Full Text] [Related]

  • 5. Molecular shape and immunogenicity of meningococcal polysaccharide group A conjugate vaccine.
    Xu M, Xing X, Wu Z, Du Y, Hu T.
    Vaccine; 2015 Oct 26; 33(43):5815-5821. PubMed ID: 26387430
    [Abstract] [Full Text] [Related]

  • 6. The phenyl linker markedly increases the immunogenicity of the pneumococcal polysaccharide conjugate vaccine.
    Wei D, Yu W, Hu C, Shen L, Hu T.
    Biotechnol Lett; 2018 Aug 26; 40(8):1263-1270. PubMed ID: 29802568
    [Abstract] [Full Text] [Related]

  • 7. Quality, immunogenicity and stability of meningococcal serogroup ACWY-CRM197, DT and TT glycoconjugate vaccines.
    Beresford NJ, Martino A, Feavers IM, Corbel MJ, Bai X, Borrow R, Bolgiano B.
    Vaccine; 2017 Jun 16; 35(28):3598-3606. PubMed ID: 28408122
    [Abstract] [Full Text] [Related]

  • 8. Comparison of Neisseria meningitidis serogroup W135 polysaccharide-tetanus toxoid conjugate vaccines made by periodate activation of O-acetylated, non-O-acetylated and chemically de-O-acetylated polysaccharide.
    Gudlavalleti SK, Lee CH, Norris SE, Paul-Satyaseela M, Vann WF, Frasch CE.
    Vaccine; 2007 Nov 14; 25(46):7972-80. PubMed ID: 17936445
    [Abstract] [Full Text] [Related]

  • 9. Immunogenicity and safety of a meningococcal A conjugate vaccine in Africans.
    Sow SO, Okoko BJ, Diallo A, Viviani S, Borrow R, Carlone G, Tapia M, Akinsola AK, Arduin P, Findlow H, Elie C, Haidara FC, Adegbola RA, Diop D, Parulekar V, Chaumont J, Martellet L, Diallo F, Idoko OT, Tang Y, Plikaytis BD, Kulkarni PS, Marchetti E, LaForce FM, Preziosi MP.
    N Engl J Med; 2011 Jun 16; 364(24):2293-304. PubMed ID: 21675889
    [Abstract] [Full Text] [Related]

  • 10. The tetravalent meningococcal serogroups A, C, W-135, and Y tetanus toxoid conjugate vaccine is immunogenic with a clinically acceptable safety profile in subjects previously vaccinated with a tetravalent polysaccharide vaccine.
    Dbaibo G, Van der Wielen M, Reda M, Medlej F, Tabet C, Boutriau D, Sumbul A, Anis S, Miller JM.
    Int J Infect Dis; 2012 Aug 16; 16(8):e608-15. PubMed ID: 22704725
    [Abstract] [Full Text] [Related]

  • 11. Development of meningococcal polysaccharide conjugate vaccine that can elicit long-lasting and strong cellular immune response with hepatitis B core antigen virus-like particles as a novel carrier protein.
    Xu L, Li Z, Su Z, Yang Y, Ma G, Yu R, Zhang S.
    Vaccine; 2019 Feb 08; 37(7):956-964. PubMed ID: 30655174
    [Abstract] [Full Text] [Related]

  • 12. Structure activity studies on group C meningococcal polysaccharide-protein conjugate vaccines: effect of O-acetylation on the nature of the protective epitope.
    Michon F, Huang CH, Farley EK, Hronowski L, Di J, Fusco PC.
    Dev Biol (Basel); 2000 Feb 08; 103():151-60. PubMed ID: 11214233
    [Abstract] [Full Text] [Related]

  • 13. Randomized trial to assess immunogenicity and safety of Haemophilus influenzae type b and Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine in infants.
    Marchant CD, Miller JM, Marshall GS, Blatter M, Aris E, Friedland LR, Boutriau D, HibMenCY-TT 005 Study Group.
    Pediatr Infect Dis J; 2010 Jan 08; 29(1):48-52. PubMed ID: 20035207
    [Abstract] [Full Text] [Related]

  • 14. Effects of prior polysaccharide vaccination on magnitude, duration, and quality of immune responses to and safety profile of a meningococcal serogroup C tetanus toxoid conjugate vaccination in adults.
    Southern J, Deane S, Ashton L, Borrow R, Goldblatt D, Andrews N, Balmer P, Morris R, Kroll JS, Miller E.
    Clin Diagn Lab Immunol; 2004 Nov 08; 11(6):1100-4. PubMed ID: 15539513
    [Abstract] [Full Text] [Related]

  • 15. MenACWY-TT vaccine for active immunization against invasive meningococcal disease.
    Papaevangelou V, Spyridis N.
    Expert Rev Vaccines; 2012 May 08; 11(5):523-37. PubMed ID: 22827239
    [Abstract] [Full Text] [Related]

  • 16. Primary and booster mucosal immune responses to meningococcal group A and C conjugate and polysaccharide vaccines administered to university students in the United Kingdom.
    Zhang Q, Lakshman R, Burkinshaw R, Choo S, Everard J, Akhtar S, Finn A.
    Infect Immun; 2001 Jul 08; 69(7):4337-41. PubMed ID: 11401971
    [Abstract] [Full Text] [Related]

  • 17. Preclinical immunogenicity and functional activity studies of an A+W meningococcal outer membrane vesicle (OMV) vaccine and comparisons with existing meningococcal conjugate- and polysaccharide vaccines.
    Tunheim G, Arnemo M, Næss LM, Fjeldheim ÅK, Nome L, Bolstad K, Aase A, Mandiarote A, González H, González D, García L, Cardoso D, Norheim G, Rosenqvist E.
    Vaccine; 2013 Dec 09; 31(51):6097-106. PubMed ID: 24120679
    [Abstract] [Full Text] [Related]

  • 18. Murine immune responses to Neisseria meningitidis group C capsular polysaccharide and a thymus-dependent toxoid conjugate vaccine.
    Rubinstein LJ, García-Ojeda PA, Michon F, Jennings HJ, Stein KE.
    Infect Immun; 1998 Nov 09; 66(11):5450-6. PubMed ID: 9784556
    [Abstract] [Full Text] [Related]

  • 19. A randomized trial to assess safety and immunogenicity of alternative formulations of a quadrivalent meningococcal (A, C, Y, and W-135) tetanus protein conjugate vaccine in toddlers.
    McVernon J, Nolan T, Richmond P, Reynolds G, Nissen M, Lambert SB, Marshall H, Papa T, Rehm C.
    Pediatr Infect Dis J; 2012 Jan 09; 31(1):e15-23. PubMed ID: 22094636
    [Abstract] [Full Text] [Related]

  • 20. Carrier priming with CRM 197 or diphtheria toxoid has a different impact on the immunogenicity of the respective glycoconjugates: biophysical and immunochemical interpretation.
    Pecetta S, Lo Surdo P, Tontini M, Proietti D, Zambonelli C, Bottomley MJ, Biagini M, Berti F, Costantino P, Romano MR, Study Group.
    Vaccine; 2015 Jan 03; 33(2):314-20. PubMed ID: 25448110
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.